Breast Cancer

Experts review and share their perspectives on key findings in breast cancer presented at the 2019 SABCS.

Share

Program Content

Activities

  • 2019 SABCS Preview
    A Look Ahead to the 2019 SABCS Meeting
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2019

    Expires: December 08, 2020

  • Key HER2+ Studies: SABCS 2019
    I’m Excited About New Agents for HER2+ Breast Cancer From SABCS 2019! Here’s Why.
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 13, 2020

    Expires: January 11, 2021

  • CT Insights: SABCS 2019
    New Developments in Chemotherapy-Based Treatment for Breast Cancer: Insights From SABCS 2019
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 27, 2020

    Expires: January 25, 2021

  • HR+ BC Insights: SABCS 2019
    New Developments in HR-Positive/HER2-Negative Breast Cancer: Insights From SABCS 2019
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 31, 2020

    Expires: January 29, 2021

  • SABCS 2019: New Insights in BC
    New Insights in Breast Cancer: Independent Conference Coverage of SABCS 2019
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 02, 2020

    Expires: March 01, 2021

Activities

HER2CLIMB: Tucatinib in HER2+ MBC
HER2CLIMB: Phase II Study of Tucatinib Plus Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

CONTROL: Neratinib-Associated Diarrhea
CONTROL: Phase II Trial of Antidiarrheal Prophylaxis or Neratinib Dose Escalation for Neratinib-Associated Diarrhea in Patients With HER2+ Early BC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

APHINITY: CT + Trastuzumab/Pertuzumab Updated OS
APHINITY: Interim OS Analysis of Adjuvant CT Plus Trastuzumab With vs Without Pertuzumab for Patients With HER2+ EBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

Neratinib for <i>HER2</i>-mutant ABC
plasmaMATCH Cohort B: Neratinib ± Fulvestrant for Patients With HER2 Mutation–Positive Advanced Breast Cancer as Identified by ctDNA Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

INFORM Neoadjuvant Trial
INFORM: Randomized Phase II Study of Neoadjuvant Cisplatin vs AC in Newly Diagnosed Breast Cancer With Germline BRCA Mutations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

DESTINY-Breast01
DESTINY-Breast01: Phase II Study of Trastuzumab Deruxtecan (DS-8201a) in HER2+ Advanced Breast Cancer Previously Treated With T-DM1
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2019

Expires: December 16, 2020

NSABP B-42 10-Yr Follow-up
NSABP B-42 10-Yr Follow-up: Extended Adjuvant Letrozole After Previous Adjuvant AI Therapy in Postmenopausal Women With HR+ Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

KEYNOTE-522: pCR by Subgroups
KEYNOTE-522 Study of Neoadjuvant Pembrolizumab vs Placebo in Combination With Chemotherapy for Early-Stage TNBC: Subgroup Analysis of pCR
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

ATEMPT: T-DM1 vs TH in Stage I EBC
Phase II ATEMPT: Analysis of Adjuvant Trastuzumab Emtansine (T-DM1) vs Paclitaxel Plus Trastuzumab in Patients With Stage I HER2-Positive Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2019

Expires: December 17, 2020

PEARL: Palbociclib + ET vs CAPE in HR+ MBC
PEARL: Palbociclib + Endocrine Therapy vs Capecitabine in Postmenopausal Women With HR+/HER- MBC and Previous AI Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

SOPHIA 2nd Interim OS Analysis
SOPHIA: Second Interim OS Analysis of Margetuximab + CT vs Trastuzumab + CT for HER2+ MBC After Previous HER2 Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

plasmaMATCH: ctDNA to Direct Tx in Adv BC
plasmaMATCH (CRUK/15/010): Evaluation of Circulating Tumor DNA Testing to Direct Targeted Therapies in Patients with Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

Oral vs IV Paclitaxel in MBC
Oral Paclitaxel With P-Glycoprotein Pump Inhibitor Encequidar vs Intravenous Paclitaxel in Metastatic Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

T-DXd and QTc/PK in MBC
Phase I Study to Assess the Effect of Trastuzumab Deruxtecan on QTc Interval and Pharmacokinetics in HER2-Expressing Metastatic or Unresectable Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

Neratinib in HER2+ MBC
Impact of Neratinib on CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer: Analysis of Data From Phase II/III Trials
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

Neoadj CT ± Atezo in TNBC
NeoTRIPaPDL1 Michelangelo: Neoadjuvant Chemotherapy ± Atezolizumab in Early, High-Risk and Locally Advanced TNBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen